Published in Lab Law Weekly, March 10th, 2006
The licensing agreement stipulates that ICM will pay royalties to Medistem for the use of Medistem's technologies. In addition to royalties, all intellectual property developed by ICM through their research and clinical treatment programs will be the property of Medistem.
ICM has acquired the lease for their...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.